Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EPS (Basic): 2019-2024

Historic EPS (Basic) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to -$1.85.

  • Mirum Pharmaceuticals' EPS (Basic) rose 120.00% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.85, marking a year-over-year increase of 59.13%. This contributed to the annual value of -$1.85 for FY2024, which is 53.75% up from last year.
  • Mirum Pharmaceuticals' EPS (Basic) amounted to -$1.85 in FY2024, which was up 53.75% from -$4 recorded in FY2023.
  • Mirum Pharmaceuticals' 5-year EPS (Basic) high stood at -$1.85 for FY2024, and its period low was -$4.09 during FY2020.
  • Moreover, its 3-year median value for EPS (Basic) was -$4 (2023), whereas its average is -$3.29.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' EPS (Basic) plummeted by 44.77% in 2022, and later skyrocketed by 53.75% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' EPS (Basic) (Yearly) stood at -$4.09 in 2020, then soared by 32.27% to -$2.77 in 2021, then slumped by 44.77% to -$4.01 in 2022, then increased by 0.25% to -$4 in 2023, then soared by 53.75% to -$1.85 in 2024.